Story perspectives

FDA Approves Icotyde: Game-Changer for Plaque Psoriasis Treatment

3/18/2026

Summary

Story summary

The FDA approved Johnson & Johnson's Icotyde, an oral pill, to treat moderate-to-severe plaque psoriasis in adults and children 12 and older.
Icotyde offers a once-daily regimen, a first-of-its-kind treatment.
Analysts project Icotyde could reach over $8 billion in peak sales as it competes with Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi.
Icotyde blocks interleukin-23 (IL-23), the inflammation-related protein, and is being studied for ulcerative colitis and Crohn's disease.

1 of 1

Story summary

The FDA approved Johnson & Johnson's Icotyde, an oral pill, to treat moderate-to-severe plaque psoriasis in adults and children 12 and older.
Icotyde offers a once-daily regimen, a first-of-its-kind treatment.
Analysts project Icotyde could reach over $8 billion in peak sales as it competes with Bristol Myers Squibb's Sotyktu and AbbVie's Skyrizi.
Icotyde blocks interleukin-23 (IL-23), the inflammation-related protein, and is being studied for ulcerative colitis and Crohn's disease.